Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy in first-line treatment of driver-negative advanced NSCLC
ChiCTR2000038783Phase 2Not yet recruiting
- Sponsor
- The Third People's Hospital of Zhengzhou
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Third People's Hospital of Zhengzhou. Primary endpoints: progression-free survival, overall survival and 3 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000038783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038783.